R&D

R&D is
the heart of our mission to develop global medicines for incurable diseases.

R&D Pipeline for New Medicine

R&D_Pipeline

 US,   China,  Japan )
R&D_Pipeline
Therapeutic Area Project code Indication Discovery Preclinical Phase1 Phase2 Phase3 BLA/NDA Review Partners
Immunology HL161 (batoclimab) Myasthenia gravis
(MG)
US/EU IMMUNOVANT  (US/EU/Japan)

하버바이오메드
(China)
Japan
China
Thyroid eye disease
(TED)
US/EU IMMUNOVANT 
(US/EU/Japan)
하버바이오메드
(China)
Japan
China
Warm autoimmune
hemolytic anemia
(WAIHA)
US/EU IMMUNOVANT
(US/EU)
Neuromyelitis optica
(NMOSD)
China 하버바이오메드
(China)
Immune thrombocytopenia
(ITP)
China 하버바이오메드
(China)
Grave's Disease
(GD)
US/EU IMMUNOVANT
(US/EU)
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
US IMMUNOVANT 
(US/EU)
Oncology HL186
Anti-TIM3 Ab
Immuno-oncology US 대웅제약
HL187
Anti-TIGIT Ab
Immuno-oncology US 대웅제약
Ophthalmology HL036
(tanfanercept)
Dry eye disease (DED) US 대웅제약

하버바이오메드
China
HL189
(tanfanercept)
Non-Infectious uveitis (NIU) US
Neurology HL192
(ATH399A)
Parkinson’s Disease US 대웅제약

Nurron